

Company

Dr. Sulaiman Al Habib
Medical Services
Group
4Q25 Result Review

Rating

Buy

Bloomberg Ticker


SULAIMAN AB

Date

26 February 2026

Results

Target Price SAR	278.0
Total Return	20.6%



Current Market Price (SAR)	235.6
52wk High / Low (SAR)	290.6/227.7
12m Average Vol. (mn)	0.2
Mkt. Cap. (USD/SAR mn)	21,983/82,460
Shares Outstanding (mn)	350.0
Free Float (%)	29.1%
3m ADTV (SAR mn)	46.4
6m ADTV (SAR mn)	50.7
P/E'26e (x)	28.7
EV/EBITDA'26e (x)	23.4
Dividend Yield '26e (%)	2.6%
Price Perf. (1m/3m) (%)	-11.0/-3.8

Revenue grows strongly in 4Q25, meeting our expectations

Dr. Sulaiman Al Habib's revenue in 4Q25 climbed 18% YoY, meeting our estimate. In FY25, revenue surged 22% YoY, driven by increased patient volume and improved occupancy across both the hospital and pharmacy segments.

Net profit rises 6% YoY, driven by revenue, beating our estimate

Strong revenue growth drove net profit growth of 6% YoY in 4Q25, beating our estimate. Net profit in FY25 edged up 4% YoY on the back of solid revenue growth. However, net profit growth was constrained by fixed operating costs associated with the new hospitals launched during FY24-25 that are currently in the ramp-up stage.

U Capital View

We expect Dr. Sulaiman's earnings growth to pick up this year as the new hospitals progress toward optimum utilization levels. The addition of more projects during FY28-29 will enhance earnings potential. Hence, we maintain our SAR 278.0 target price on the stock. The company's BoD proposed a DPS of SAR 1.31 for 4Q25 (4Q24: SAR 1.23), indicating a payout ratio of ~70%, aligning with its historical trend.

Research Department

Email: ubhar-research@u-capital.net

For our
last report

**Financial Summary**

SAR mn	4Q24	1Q25	2Q25	3Q25	4Q25	4Q25e	YoY	QoQ	Var.	FY24	FY25	YoY
P&L												
Revenue	3,129	3,158	3,384	3,463	3,701	3,631	18%	7%	2%	11,200	13,707	22%
Gross profit	997	1,028	1,066	1,050	1,063	1,093	7%	1%	-3%	3,744	4,207	12%
Operating profit	624	626	645	666	682	641	9%	3%	6%	2,356	2,619	11%
Net profit	614	557	591	602	651	577	6%	8%	13%	2,315	2,401	4%
BS												
Sh. Equity	7,175	7,291	7,495	7,684	7,902		10%	3%		7,175	7,902	10%
Ratios												
GPM	31.9%	32.6%	31.5%	30.3%	28.7%	30.1%				33.4%	30.7%	
OPM	19.9%	19.8%	19.1%	19.2%	18.4%	17.7%				21.0%	19.1%	
NPM	19.6%	17.6%	17.5%	17.4%	17.6%	15.9%				20.7%	17.5%	
EPS, SAR	1.75	1.59	1.69	1.72	1.86	1.65				6.62	6.86	
RoE (TTM)					31.6%							
TTM P/E (x)					34.3							
Current P/B (x)					10.4							

Source: Financials, Tadawul, Bloomberg, U Capital Research

Disclaimer

Recommendation

BUY

Greater than +10%

HOLD

Between
0% and +10%

SELL

Lower than 0%

Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net

PO Box 1137, PC 111, Sultanate of Oman

Tel: +968 2494 9036 | **Fax:** +968 2494 9099 | **Email:** research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.